Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,000 shares of the life sciences company’s stock after selling 30,000 shares during the period. Factory Mutual Insurance Co. owned 0.07% of Illumina worth $14,476,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. V Square Quantitative Management LLC increased its position in Illumina by 55.6% in the 4th quarter. V Square Quantitative Management LLC now owns 3,466 shares of the life sciences company’s stock valued at $483,000 after acquiring an additional 1,239 shares during the period. Chicago Partners Investment Group LLC acquired a new position in shares of Illumina during the fourth quarter valued at $264,000. Syon Capital LLC bought a new stake in shares of Illumina during the fourth quarter valued at about $548,000. Wahed Invest LLC lifted its holdings in Illumina by 6.0% in the fourth quarter. Wahed Invest LLC now owns 2,695 shares of the life sciences company’s stock worth $375,000 after purchasing an additional 153 shares during the period. Finally, Vanguard Group Inc. grew its position in Illumina by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 18,178,513 shares of the life sciences company’s stock valued at $2,531,176,000 after buying an additional 210,755 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.2 %

NASDAQ:ILMN traded up $1.78 on Friday, hitting $145.54. 1,650,192 shares of the company’s stock traded hands, compared to its average volume of 2,031,084. The company has a market cap of $23.18 billion, a PE ratio of -7.60 and a beta of 1.15. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $148.19. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The firm has a 50-day moving average price of $130.19 and a 200-day moving average price of $120.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The firm’s revenue was down 5.4% on a year-over-year basis. Equities analysts anticipate that Illumina, Inc. will post 3.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of research analyst reports. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Robert W. Baird lifted their price target on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. TD Cowen upgraded Illumina from a “hold” rating to a “buy” rating and upped their price objective for the company from $126.00 to $144.00 in a report on Wednesday, August 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $252.00 target price on shares of Illumina in a research note on Thursday. Finally, StockNews.com assumed coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $150.05.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.